Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Benitec Biopharma (BNTC) Consolidated Net Income (2019 - 2025)

Historic Consolidated Net Income for Benitec Biopharma (BNTC) over the last 7 years, with Q2 2025 value amounting to -$8.8 million.

  • Benitec Biopharma's Consolidated Net Income fell 9010.37% to -$8.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$38.5 million, marking a year-over-year decrease of 7825.91%. This contributed to the annual value of -$38.5 million for FY2025, which is 7825.91% down from last year.
  • Latest data reveals that Benitec Biopharma reported Consolidated Net Income of -$8.8 million as of Q2 2025, which was down 9010.37% from -$14.5 million recorded in Q1 2025.
  • Benitec Biopharma's 5-year Consolidated Net Income high stood at -$3.5 million for Q1 2022, and its period low was -$14.5 million during Q1 2025.
  • For the 5-year period, Benitec Biopharma's Consolidated Net Income averaged around -$5.8 million, with its median value being -$4.8 million (2021).
  • Per our database at Business Quant, Benitec Biopharma's Consolidated Net Income soared by 1178.57% in 2024 and then crashed by 25010.86% in 2025.
  • Benitec Biopharma's Consolidated Net Income (Quarter) stood at -$4.8 million in 2021, then decreased by 15.95% to -$5.6 million in 2022, then decreased by 23.38% to -$6.9 million in 2023, then tumbled by 43.98% to -$10.0 million in 2024, then grew by 11.86% to -$8.8 million in 2025.
  • Its Consolidated Net Income stands at -$8.8 million for Q2 2025, versus -$14.5 million for Q1 2025 and -$10.0 million for Q4 2024.